LB13. Trivalent Hepatitis B (HepB) Vaccine Yields Superior Seroprotection Rates in Adults: Results from the Phase 3 Double-Blind, Randomized Study Comparing Immunogenicity and Safety of a 3-Dose Regimen of Sci-B-Vac™ and Engerix B® (PROTECT)

BACKGROUND: Many adults fail to achieve seroprotection after receiving 3 doses of monovalent HepB vaccines such as Engerix-B® and the response decreases with age and with common co-morbidities. Sci-B-Vac™ is a trivalent HepB vaccine produced in mammalian cells, adjuvanted with aluminum hydroxide, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Vesikari, Timo, Langley, Joanne M, Smith, Bruce, van Damme, Pierre, Leroux-Roels, Isabel, Leroux-Roels, Geert, Spaans, Johanna, Machluf, Nathalie, Yassin-Rajkumar, Bebi, Anderson, Dave, Popovic, Vlad, Diaz-Mitoma, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810620/
http://dx.doi.org/10.1093/ofid/ofz415.2496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810620/
http://dx.doi.org/10.1093/ofid/ofz415.2496

Ejemplares similares